JUNS MDXXF Pharmala Biotech executes definitive license agreement granting Jupiter Neurosciences exclusive U.S. rights to ala-002 Pharmala B
JUNS MDXXF Pharmala Biotech executes definitive license agreement granting Jupiter Neurosciences exclusive U.S. rights to ala-002 Pharmala Biotech - deal valued up to $100M including $3.33M upfront and milestones plus royalties - Upfront payment of $3.33M: $1.50M cash, $1.83M in Jupiter stock - Development and regulato